Ticker brief
NUVL
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
6
authors 14d
5
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-19 → 2026-06-22 · now +0.35 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @PersimmonTI | A | -0.32 | 2 | +0.38 |
| @BiopharmIQ | B | · | 1 | +0.00 |
| @financespotnews | C | -0.87 | 1 | +0.50 |
| @bioinvestor24 | A | +1.35 | 1 | +0.00 |
| @akishore | C | +1.67 | 1 | +0.35 |
Recent signals6of 6 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-06-22 | @akishore | +0.35 | Says ABBV's 49% premium may draw attention to mid-cap immunology players NUVL and TVTX. | · | tweet ↗ |
| 2026-06-21 | @bioinvestor24 | +0.00 | TNGX no longer cheap; BP buying ERAS/TNGX could pressure RVMD, molecular glues popular. | · | tweet ↗ |
| 2026-06-21 | @PersimmonTI | +0.50 | BioSpace data: LLY has half of 2026 upfront M&A spend; GSK/NUVL and ABBV/APGE discussed. | · | tweet ↗ |
| 2026-06-20 | @PersimmonTI | +0.25 | Takeaways from Perceptive's Edelman on biotech investing, position sizing and drug questions. | · | tweet ↗ |
| 2026-06-20 | @financespotnews | +0.50 | GSK announced $10.6B all-cash Nuvalent acquisition at $124/share, 40% premium. | · | tweet ↗ |
| 2026-06-19 | @BiopharmIQ | +0.00 | Reports ABBV reportedly set to acquire APGE for $10.9B and frames big pharma paying up. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.